IL RUOLO DI BMS NELLO SVILUPPO DELL IMMUNO-ONCOLOGIA
|
|
- Nora Wheeler
- 5 years ago
- Views:
Transcription
1 IL RUOLO DI BMS NELLO SVILUPPO DELL IMMUNO-ONCOLOGIA Milano, 1 Febbraio 2017 Elisabetta Calabrese, MD PhD Bristol-Myers Squibb Mercury number Italy: IOIT17NP
2 AGENDA The past: Story of Immuno-Oncology BMS) The present: Our Commitment to I-O: Extensive Pipeline The future: Objectives and innovation
3 EVOLUTION OF CANCER THERAPY: IMMUNO-ONCOLOGY (I-O) IS NOW A PILLAR OF CANCER THERAPY Surgery 1846 Radiation Therapy 1901 Chemotherapy 1946 Immunotherapy interferon-α 1986 interleukin Immuno-Oncology sipuleucel-t 2010 ipilimumab 2011 nivolumab 2014 Targeted Therapy imatinib 2001 gefitinib 2003 DeVita VT Jr, Chu E. Cancer Res. 2008;68(21): ; The American Cancer Society. The History of Cancer. Available from: cancer.org/cancer/cancerbasics/thehistoryofcancer/. Accessed September 2014; Finn OJ. Ann Oncol. 2012;23(suppl 8):viii6 viii9; Mansh M. Yale J Biol Med. 2011;84: ; Kirkwood JM, et al. CA Cancer J Clin. 2012;62:
4 IMMUNOEDITING: THE ROLE OF THE IMMUNE SYSTEM IN CANCER DEVELOPMENT AND PROGRESSION Elimination Cancer immunosurveillance Effective antigen processing/presentation Effective activation and function of effector cells eg, T-cell activation without co-inhibitory signals Equilibrium Cancer dormancy Genetic instability Tumor heterogeneity Immune selection Escape Cancer progression Tumors may avoid elimination by the immune system through outgrowth tumor cells that can suppress, disrupt, or escape the immune system Activated T cells NK cell Treg Tumor cell Cytokines Normal cells NK=natural killer. Vesely MD, et al. Ann Rev Immunol. 2011;29:
5 TUMORS USE COMPLEX, OVERLAPPING MECHANISMS TO EVADE AND SUPPRESS THE IMMUNE SYSTEM A. Ineffective presentation of tumor antigens (eg, downregulation of MHC I) B. Recruitment of immunosuppressive cells with inactive T cells (eg, Tregs, MDSCs) APC Inactive T cell Active T cell Tumorassociated antigens Treg Tumor cells C. Tumor release of immunosuppressive factors (eg, TGF-β, IDO, IL-10) CTLA-4=cytotoxic T-lymphocyte-associated protein 4; IDO= indoleamine 2,3-dioxygenase; IL=interleukin; MDSC=myeloid-derived suppressor cell; MHC=major histocompatibility complex; TGF-β=transforming growth factor beta. Vesely MD et al. Ann Rev Immunol. 2011;29: Immunosuppressive factors D. T-cell checkpoint dysregulation (eg, PD-1, CTLA-4)
6 REGULATING THE T CELL IMMUNE RESPONSE Activating receptors CD28 OX40 CD137 Agonistic antibodies T cell stimulation Inhibitory receptors CTLA-4 PD-1 TIM-3 LAG-3 Antagonistic (blocking) antibodies T cell responses are regulated through a complex balance of inhibitory (checkpoint) and activating signals Tumors can dysregulate checkpoint and activating pathways, and consequently immune response Targeting these pathways is an evolving approach to cancer therapy, designed to promote an immune response The image shows only a selection of the receptors/pathways involved. LAG-3=lymphocyte-activation gene 3; TIM-3=T-cell immunoglobulin domain and mucin domain 3. Adapted from Mellman I, et al. Nature. 2011:480; ; Pardoll DM. Nat Rev Cancer. 2012;12:
7 THE DISCOVERY OF IPILIMUMAB AND NIVOLUMAB Mouse CTLA4 Cloned 1 CTLA4 Binds to B7 2 CTLA-4 is negative regulator of T cell 3-7 Jim Allison mouse cancer model, Inhibition of CTLA4 as anti-cancer Therapy 8 Agreement to develop anti-ctla4 for clinical use 9 Cloning of ipilimumab 10 Yervoy (ipilimumab) Ipilimumab FIH approved in US Opidivo (nivolumab) approved in US Nivolumab FIH Nivolumab discovered PD-1 is a negative signaling molecule Brunet et al (INSERM, Marseille) Nature. 2. Linsely et al (BMS Seattle) JEM 1991 and 1992; 3.Walunas, Bluestone et al. Immunity, 4. Green et al. Immunity 1994, 5.Waterhouse, Mak et al Science, 6. Tivol, Bluestone, Sharp et al Immunity, 7.Krummel and Allison Jem 1995, 8. Leach, Krummel, Allison. Science 1996, 9. Korman, Lonberg, Allison, 10. Keler, Korman et al JIM 2003 (Medarex), 11. Honjo, KO,
8 1996: INHIBITION OF CTLA4 AS ANTI-CANCER THERAPY CTLA-4 blockade can induce antitumor immunity Leach, Krummel, Allison. Science 1996
9 POOLED ANALYSIS OF LONG-TERM OS FROM PHASE 2 AND 3 TRIALS OF IPILIMUMAB: INCLUDING EAP 1.0 Proportion Alive N= 4846 Median OS, months (95% CI): 9.5 ( ) 3-year OS rate, % (95% CI): 21 (20 22) Ipilimumab CENSORED Months Patients at Risk Ipilimumab Schadendorf D, et al. J Clin Oncol.2015.
10 THE DISCOVERY OF IPILIMUMAB AND NIVOLUMAB Mouse CTLA4 Cloned 1 CTLA4 Binds to B7 2 CTLA-4 is negative regulator of T cell 3-7 Jim Allison mouse cancer model, Inhibition of CTLA4 as anti-cancer Therapy 8 Agreement to develop anti-ctla4 for clinical use 9 Cloning of ipilimumab 10 Yervoy (ipilimumab) Ipilimumab FIH approved in US Opidivo (nivolumab) approved in US Nivolumab FIH Nivolumab discovered PD-1 is a negative signaling molecule Brunet et al (INSERM, Marseille) Nature. 2. Linsely et al (BMS Seattle) JEM 1991 and 1992; 3.Walunas, Bluestone et al. Immunity, 4. Green et al. Immunity 1994, 5.Waterhouse, Mak et al Science, 6. Tivol, Bluestone, Sharp et al Immunity, 7.Krummel and Allison Jem 1995, 8. Leach, Krummel, Allison. Science 1996, 9. Korman, Lonberg, Allison, 10. Keler, Korman et al JIM 2003 (Medarex), 11. Honjo, KO,
11 NIVOLUMAB: MECHANISM OF ACTION Recognition of tumor by T cell through MHC/antigen interaction mediates IFNγ release and PD-L1/2 upregulation on tumor Priming and activation of T cells through MHC/antigen & CD28/B7 interactions with antigen-presenting cells IFNγ IFNγR MHC T-cell receptor T-cell receptor MHC Tumor cell PD-L1 PD-L2 PD-1 Shp-2 PI3K NFκB Other T cell Shp-2 CD28 PD-1 B7 PD-L1 Dendritic cell PD-1 PD-1 PD-L2 Nivolumab blocks the PD-1 receptor CD28/B7, cluster of differentiation 28/B7; IFNγ, interferon-gamma; IFNγR, IFNγ receptor; MHC, major histocompatibility complex; NFκB, nuclear factor kappa B; PD-L1, programmed death ligand-1; PD-L2, programmed death ligand-2; PI3K, phosphoinositide-3 kinase; Shp-2, ubiquitously expressed tyrosine-specific protein phosphatase. Pardoll DM. Nat Rev Cancer. 2012;12: Adapted from Pardoll [1]
12 NIVOLUMAB: 5 STUDIES EARLY STOPPED IN 18 MONTHS SUPERIORITY IN OS PRIMARY ENDPOINTS Checkmate 066 Melanoma Checkmate 057 nsq-nsclc Checkmate 141 SCCHN June 2014 Jan 2015 Apr 2015 Jul 2015 Jan 2016 Checkmate 017 Sq-NSCLC Checkmate 025 RCC
13 CHECKMATE 066: MELANOMA OVERALL SURVIVAL Long et al, SMR 2014
14 CHECKMATE 017: SQUAMOUS NSCLC OVERALL SURVIVAL OS (%) yr OS rate = 42% mos mo, (95% CI) Nivolumab Nivolumab n = (7.3, 13.3) Docetaxel n = (5.1, 7.3) # events HR = 0.59 (95% CI: 0.44, 0.79), P = Docetaxel 10 1-yr OS rate = 24% Time (months) Number of Patients at Risk Nivolumab Docetaxel Symbols represent censored observations Spiegel et al, ASCO 2015
15 CHECKMATE 057: NON-SQUAMOUS NSCLC OVERALL SURVIVAL Nivolumab (n = 292) Docetaxel (n = 290) mos, mo HR = 0.73 (96% CI: 0.59, 0.89); P = OS (%) yr OS rate = 39% 1-yr OS rate = 51% Nivolumab 20 Docetaxel Number of Patients at Risk Nivolumab Docetaxel Time (months) Paz Ares et al, ASCO 2015
16 RECOGNITION OF I-O Eight New England Journal of Medicine Publications in 10 months A. Snyder, M.D., et al. November 19, 2014 S.M. Ansell, M.D., et al. December 6, 2014 J. Larkin, et al. May 31, 2015 C. Robert, M.D., Ph.D., et al. November 16, 2014 M.A. Postow, M.D., et al. April 20, 2015 Sagar Lonial, M.D., et al. June 2, 2015 J. Brahmer, M.D., et al. May 31, 2015 H. Borghaei M.D., et al. Sept
17 CHECKMATE 025: NON-SQUAMOUS NSCLC OVERALL SURVIVAL Sharma et al, ESMO 2015 Overall Survival (Probability) Everolimus Median OS, months (95% CI) Nivolumab 25.0 (21.8 NE) Everolimus 19.6 ( ) HR (98.5% CI): 0.73 ( ) P = Nivolumab No. of patients at risk Months Nivolumab Everolimus Minimum follow-up was 14 months. 17
18 CHECKMATE 141: HEAD & NECK CARCINOMA OVERALL SURVIVAL Overall Survival (% of patients) 100 Median OS, mo (95% CI) Nivolumab (n = 240) 7.5 ( ) Investigator s Choice (n = 121) 5.1 ( ) HR (97.73% CI) 0.70 ( ) Months No. at Risk Nivolumab Investigator s Choice Gillison et al, AACR year OS rate (95% CI) 36.0% ( ) 16.6% ( ) p-value
19 SURVIVAL AS MAJOR BENEFIT Checkmate 066 Melanoma Checkmate 017 Sq-NSCLC Checkmate 057 nsq-nsclc Checkmate 025 RCC Checkmate 141 SCCHN PRIMARY ENDPOINT: OVERALL SURVIVAL Secondary Endpoint: PFS
20 CHECKMATE 026: NIVO VS CHEMO IN 1L NSCLC OVERALL SURVIVAL ( 5% PD-L1+) OS (%) Months Median OS, months (95% CI) Nivolumab n = (11.7, 17.4) No. of patients at risk: Nivolumab Chemotherapy Socinsky et al, ESMO % in the chemotherapy arm had subsequent nivolumab therapy 43.6% in the nivolumab arm had subsequent systemic therapy Chemotherapy n = (10.7, 17.1) 1-year OS rate, % HR = 1.02 (95% CI: 0.80, 1.30) Chemotherapy Nivolumab All randomized patients ( 1% PD-L1+): HR = 1.07 (95% CI: 0.86, 1.33) 20
21 NEOADJUVANT NIVOLUMAB IN NSCLC EXPLORATORY ANALYSES OF RESPONSE TO TREATMENT Radiographic response (N=18) RECIST 1.1 N (%) Partial Response 4 (22) Stable Disease 13 (72) Progressive Disease 1 (6) Pathologic downstaging from pre-treatment clinical stage (N=18) N (%) Yes 7 (39) No 11 (61) Tumor pathologic response after neoadjuvant anti-pd-1 (N=17) Resected Tumors Major pathologic response Minor or no response Percent Pathologic Response <10% residual viable tumor cells defines major pathologic response per Pataer et al. JTO % (95% CI 20-61% ) of per protocol patients, 7 of 18, had <10% residual viable tumor at resection 1 patient had a pathologic complete response Forde et al, ESMO 2016
22 CA : IPILIMUMAB IN ADJUVANT MELANOMA OVERALL SURVIVAL Patients Alive (%) Ipilimumab Placebo Deaths/patients 162/ /476 HR (95.1% CI) a 0.72 (0.58, 0.88) Log-rank P value a % 54% O N Number of patients at risk a Stratified by stage provided at randomization. Years Ipilimumab Placebo Eggermoint et al, ESMO 2016
23 PIPELINE RATIONALE The immune system is built on homeostatic mechanisms which can turn it on and off as appropriate Tumors exploit normal homeostatic mechanisms of the immune system to protect themselves from immune attack Our strategy works to reset the balance in favor of the immune system, and to initiate new responses that counteract the tumor s protection
24 AT THE FOREFRONT OF SCIENCE EXPLORING A DIVERSITY OF MECHANISMS At Bristol-Myers Squibb, we have a vision for the future of cancer care that is focused on Immuno-Oncology (I-O). We will continue to build upon our past discoveries and advance our current research. Bristol-Myers Squibb remains inspired by the broad potential of I-O and driven by the many patients with advanced cancer with an unmet medical need. ^ Some of the pathways described are under investigation as part of a collaboration between Bristol-Myers Squibb and other companies. * Pathways are listed by primary mechanisms. Secondary mechanisms may exist. 24
25 AT THE FOREFRONT OF SCIENCE EXPLORING EFFECTOR T-CELL MECHANISM Broad Portfolio Effector T Cell Mechanisms Activating CD137 GITR OX40 Inhibitory CTLA4 PD1 Lag3 TIGIT *Targets are listed by primary mechanisms. Secondary mechanisms may exist.
26 CD137: POTENTIATES INNATE AND ADAPTIVE IMMUNITY* CD137, or 4-1BB, is an activating receptor found on both T cells and natural killer (NK) cells 17,18 The presence of CD137 appears to be a marker for tumor reactivity the ability to react to tumor antigen and mount an immune response 19 Based on preclinical data, activation of CD137 signaling can stimulate both cytotoxic T-cell and NK-cell activity and generate a lasting memory response 20,21 The CD137 pathway is currently under investigation in Phase I and Phase II trials for advanced solid tumors and hematologic malignancies EFFECTOR T CELL MECHANISMS: Activating Pathways 26
27 LAG-3: IMPLICATED IN BOTH T-CELL EXHAUSTION AND SUPPRESSION Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor expressed on the surface of both activated cytotoxic T cells and regulatory T cells (Tregs) 43,44 The presence and activity of LAG-3 steadily increases with exposure to tumor antigen, leading to T-cell exhaustion. Tregs expressing LAG-3 also gather at tumor sites and show potent suppression of cytotoxic T cells 43,45-47 In preclinical studies, inactivation of LAG-3 allowed T cells to regain cytotoxic function 48 The LAG-3 pathway is under investigation in Phase I and Phase II trials for advanced solid tumors and hematologic malignancies EFFECTOR T CELL MECHANISMS: Inhibitory Pathways 27
28 AT THE FOREFRONT OF SCIENCE EXPLORING EFFECTOR NK-CELL MECHANISM Broad Portfolio NK Cell Mechanisms Activating SLAMF7 CD137 Inhibitory KIR *Targets are listed by primary mechanisms. Secondary mechanisms may exist.
29 KIR: REGULATES THE FIRST RESPONDERS OF IMMUNE DEFENSE NK CELL MECHANISMS: Inhibitory Pathways Killer cell immunoglobulin-like receptors (KIRs) are immune checkpoint receptors expressed on the surface of natural killer (NK) cells. Data suggest they may also be expressed on cytotoxic T cells 6,7 Inhibitory KIRs stop NK cells from killing normal cells, and tumor cells subvert this process to evade NK cell-mediated recognition and destruction 6,8 In preclinical studies, blockade of inhibitory KIRs has been shown to help restore NK cell-mediated immune activity 9,10 The KIR pathway is currently under investigation in Phase I trials for advanced solid tumors and hematologic malignancies 29
30 AT THE FOREFRONT OF SCIENCE EXPLORING TUMOR-CELL TARGET MECHANISM Broad Portfolio Tumor Cell Targeted Pathways BCR-ABL CXCR4 BET Fucosyl-GM1 HER2 Mesothelin Glypican-3 Tumor cells *Targets are listed by primary mechanisms. Secondary mechanisms may exist.
31 CXCR4: GUIDES TUMOR-CELL MIGRATION TUMOR CELL TARGETED PATHWAYS CXCR4 is a G-protein-coupled receptor in the CXC chemokine receptor family found on the surface of T cells and other immune cells. 104,105 Binding of CXCR4 to its ligand CXCL12 directs the migration and recruitment of immune cells 106,107 The CXCR4 pathway is one of the most common chemokine receptors expressed in cancer, where it plays a key role in tumor-cell proliferation, migration, metastasis, invasion, and survival Preclinical data suggest that inhibition of the CXCR4 pathway promotes the accumulation of cytotoxic T cells and impairs tumor-cell migration 112 The CXCR4 pathway is currently under investigation in Phase I/II trials for advanced solid tumors 31
32 NEED TO THINK DIFFERENTLY More than 110 Phase III clinical studies: With 15 molecules and considering only combinations of 2 drugs Avoid patients are over or undertreated TRANSLATIONAL RESEARCH SHOULD BE MUCH MORE LINKED TO CLINICAL RESEARCH
33 FOLLOWING THE PATIENT JOURNEY WITH INNOVATIVE CLINICAL TRIAL DESIGN WITH THE FRACTION * PROGRAM Innovative and Efficient Trial Design I-O therapy naive Patients with advanced NSCLC PDL1+ PDL1- Nivolumab monotherapy Innovative design to efficiently evaluate I-O combos for delivery of transformational effects I-O therapy experienced Nivo + X Combo Nivo + Y Combo Ability to explore potential benefits across range of NSCLC patients Nivo + Z Combo New Nivo Combo Novel Combo X+Y Triple Combo New treatment options provided throughout the patients journey *Fast Real-time Assessment of Combination Therapy in Immuno-ONcology Program
34 CONCLUSIONS Immunocheckpoint targets led the way to select and develop effective therapies. Combination therapy studies are ongoing to increase the outstanding results to a broader population patients Research is running much faster than ever and «personalized medicine» is needed in order to speed the process, maximize the benefits and minimize the risks Innovation in protocol design is needed
The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationASCO 2016 * Investor Meeting June 4, *American Society of Clinical Oncology, June 3-7, 2016 ASCO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ASCO 2016 * Investor Meeting June 4, 2016 *American Society of Clinical Oncology, June 3-7, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future plans
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationConcurrent Chemo- and Radiotherapy for Ororpharynx Cancer
Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Faye Johnson MD, PhD Associate Professor Thoracic/Head and Neck Medical Oncology August 2017 Objectives Review data that support concurrent chemo-
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationThe Emerging Role of Immunotherapy in Cancer Care Renato V. La Rocca, MD, FACP Norton Cancer Institute Louisville, Kentucky
The Emerging Role of Immunotherapy in Cancer Care 2015 Renato V. La Rocca, MD, FACP Norton Cancer Institute Louisville, Kentucky Renato V. La Rocca, MD, FACP I have no conflicts to disclose with respect
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationDiscover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15
Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15 Immunology in cancer The role of immunology in cancer Evolving knowledge of the immune system has provided a better understanding of
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationCowen Health Care Conference
Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationCombination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy
Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationCancer and the Immune System
NIFA Neue Impulse in Fortbildung und Ausbildung, AstraZeneca Onkologie Symposium, Vienna, October 20 th 2017 Cancer and the Immune System Translational Tumor Immunology Group, Ludwig Cancer Research Center
More informationExploring the PD-L1 Pathway
Active Within the tumor microenvironment Steps 1-3: Initiating and propagating anticancer immunity 1 may inhibit T-cell activity in the tumor microenvironment Dendritic cells capture cancer and then prime
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationImmunotherapy of Prostate Cancer
Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationCiti Global Healthcare Conference
Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationNobel Prize in Physiology or Medicine 2018
Nobel Prize in Physiology or Medicine 2018 Arunika Mukhopadhaya The Nobel Prize in Physiology or Medicine for the year 2018 was awarded to James P Allison of the United States and Tasuku Honjo of Japan
More informationChallenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies
Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationDra. Omayra Reyes, MD. Hematologist- Oncologist. Introduction to Immuno Oncology
Dra. Omayra Reyes, MD. Hematologist- Oncologist Introduction to Immuno Oncology Disclosure I have no conflicts of interest Objectives Review Basic concepts of onco- immunology. Recognize different mechanisms
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationNuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.
Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationIMMUNE CHECKPOINT BLOCKADE FOR NSCLC. Marina Chiara Garassino
IMMUNE CHECKPOINT BLOCKADE FOR NSCLC Marina Chiara Garassino Cells of the Immune System Innate immune system: Involving proteins (chemokines and cytokines) and cells, is considered to be the first line
More informationLA QUARTA ARMA CONTRO IL CANCRO
LA QUARTA ARMA CONTRO IL CANCRO Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure Employment or
More informationClinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors
Clinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors ESP/ESMO Marina Chiara GARASSINO Amsterdam 2017 September, 4th 29 European Congress of Pathology Disclosures BMS ROCHE
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationImmuno-Oncologia: verso una immunoterapia di precisione?
MEDICINA E ASSISTENZA DI PRECISIONE Firenze 22 Novembre 2017 Immuno-Oncologia: verso una immunoterapia di precisione? Anna Maria Di Giacomo Medical Oncology and Immunotherapy Center for Immuno-Oncology
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationThe Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationImmune Checkpoint Inhibitors Drug Combinations: Patients Relevance & Ways Forward
March 25, 2015 Immune Checkpoint Inhibitors Drug Combinations: Patients Relevance & Ways Forward Dr. Alexandre Passioukov p 1 Therapeutic efficacy of agents targeting immune checkpoints Introduction Deep
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More information